2017 年 11 巻 3 号 p. 160-164
The introduction of flow diverters induced a major paradigm shift in the treatment of intracranial aneurysms. Not just large and giant aneurysms, but also some of the aneurysms that are amenable to conventional coil embolization could be better treated with flow diverters because of the high efficacy and treatment durability. As such, there are two ongoing studies, the Flow Diversion in Aneurysms Trial study (FIAT) and Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device (PREMIER) study, which aim to clarify the true indication of flow diverter treatment. Simultaneously, the next generation of flow diverters is being developed by the industry. After multiple iterations of the design and improvements in the mechanical performance, industry leaders are developing a new coating technology that modifies the biocompatibility of flow diverters. Continuous improvements in the devices and compiling good quality clinical data will increase the role of the flow diverter in the treatment of intracranial aneurysms.